TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
OCUL

Ocular Therapeutix Inc

Healthcare · Biotechnology

7.30$ +1.2% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

Ocular Therapeutix Inc (OCUL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 671 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet OCUL
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
82 75 91 80 64 55 77 70 70 73 101 90 89 79 73 107 98 262 243 231 218 205 188 173 159 149 129 123 162 252 539 517 490 458 406 451 411 808 733 671
77 70 83 68 52 43 64 58 58 56 79 65 70 60 55 90 82 246 228 217 204 191 175 160 146 130 107 101 141 232 520 499 473 441 388 433 387 782 706 644
52 33 55 63 51 42 63 57 57 54 76 62 65 54 48 84 71 228 209 192 179 164 145 135 121 102 79 67 111 196 483 460 427 392 350 391 345 737 667 599
76 68 80 66 51 42 63 57 57 54 76 62 65 54 48 84 71 228 209 192 179 164 145 135 121 102 79 67 111 196 483 460 427 392 350 391 345 737 667 599
0.2 0.3 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.2 0.3 0.6 1.1 2.5 3.4 2.9 7.8 12 14 19 20 21 23 20 20 21 21 27 24 26 27 30 30 32 25 30 31 31 24 30
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.8 0.9 1.0 1.1 1.1 1.2 1.2 1.1 1.1 1.2 1.3 1.4 1.5 1.5 2.0 2.3 2.2 2.3 2.3 2.6 2.5 2.4 3.0 3.3 3.0 3.5 3.6 3.7 3.8
3.8 3.3 5.7 9.6 10 10 11 10 10 10 11 11 10 10 9.5 8.9 8.5 8.1 7.5 12 12 12 6.6 11 7.2 9.9 12 13 – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
20 23 27 32 28 29 28 25 25 37 76 81 77 82 84 102 102 186 160 150 130 117 108 107 112 114 119 119 155 161 131 139 138 143 140 145 153 154 151 151
8.2 8.3 8.7 13 11 13 13 12 13 9.2 8.6 10 11 12 11 14 23 27 27 22 25 26 24 26 29 31 30 32 35 35 24 30 36 41 38 43 49 51 48 49
3.8 1.5 0.9 2.4 4.0 5.5 6.1 6.1 6.1 – 0.7 1.0 1.1 1.1 3.3 5.4 7.5 9.6 9.7 1.5 1.6 1.6 1.7 1.8 1.7 1.6 1.8 3.8 1.9 1.6 1.5 1.7 1.7 1.9 2.2 2.6 2.8 2.8 3.2 3.1
1.7 2.1 3.8 6.3 2.6 3.6 3.5 2.1 2.8 3.0 3.9 4.0 3.5 3.3 2.8 2.7 3.2 2.7 4.2 3.9 4.2 4.6 3.4 3.7 5.3 5.1 5.4 3.6 4.0 4.4 6.5 3.7 4.0 4.2 4.6 5.9 6.3 4.2 8.0 7.0
12 14 17 15 14 12 11 9.5 8.1 25 48 49 48 49 48 47 43 41 40 50 51 51 52 53 53 54 55 53 74 75 66 67 68 69 69 70 71 71 72 73
62 52 64 48 36 26 49 46 46 36 26 8.3 11 -3.6 -11 5.3 -4.1 76 83 80 87 88 80 66 46 35 9.7 3.1 7.9 91 408 378 352 315 266 306 258 654 582 520
-161 -174 -190 -209 -224 -237 -251 -265 -280 -297 -314 -339 -358 -384 -405 -442 -454 -539 -536 -545 -542 -546 -558 -577 -601 -617 -647 -668 -668 -698 -762 -806 -843 -891 -955 -1,023 -1,092 -1,157 -1,246 -1,324
25 25 28 29 29 30 35 38 39 41 44 43 53 48 52 57 69 71 87 82 85 82 83 83 77 83 77 78 85 109 132 166 167 168 169 173 184 223 224 225

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?